Edwards Lifesciences (EW) Retained Earnings (2009 - 2026)

Edwards Lifesciences' Retained Earnings history runs 18 years deep, the most recent figure standing at $14.6 billion for Q1 2026.

• On a quarterly basis, Retained Earnings rose 5845.07% year-over-year to $14.6 billion in Q1 2026; TTM through Mar 2026 was $14.6 billion, a 5845.07% increase from a year earlier, with the FY2025 full-year figure at -$238.3 million, down 101.81% from the prior year.
• Retained Earnings grew to $14.6 billion in Q1 2026 per EW's latest filing, from -$238.3 million in the prior quarter.
• Across five years, Retained Earnings topped out at $14.6 billion in Q1 2026 and bottomed at -$264.1 million in Q2 2025.
• The 5-year median for Retained Earnings is $6.8 billion (2022), against an average of $5.3 billion.
• Across the five-year window, Retained Earnings tumbled 104.2% in 2022 and soared 5845.07% in 2026, its largest moves.
• Year by year, Retained Earnings stood at -$254.9 million in 2022, then surged by 3627.81% to $9.0 billion in 2023, then jumped by 46.42% to $13.2 billion in 2024, then plunged by 101.81% to -$238.3 million in 2025, then surged by 6235.63% to $14.6 billion in 2026.
• Per Business Quant, the three latest EW Retained Earnings figures stand at $14.6 billion (Q1 2026), -$238.3 million (Q4 2025), and -$250.4 million (Q3 2025).